Pharmaceutical stocks slumped as President-elect Donald Trump said he’s tapping Robert F. Kennedy Jr. to run the Department of Health and Human Services, potentially elevating a prominent vaccine ...
Anxious and bewildered, some drugmakers are reaching out to their lobbyists about how Robert Kennedy’s pending nomination ...
Processed foods are in the cross hairs of Robert F. Kennedy Jr., but battling major companies could collide with ...
Pharma and biotech stocks are down due to concerns over Robert F. Kennedy Jr. possibly taking the helm at HHS. Read more here ...
The FDA spent more than 15 years crafting the guidelines, which are designed to do away with industry practices that downplay ...
The US Food and Drug Administration approved Augtyro in 2023 for the treatment of ROS1-positive advanced NSCLC. Earlier this year, the FDA also approved the drug for adult and pediatric patients 12 ...
Many companies just iterate indefinitely without ever making progress toward an actual drug,” said one biotech VC on a panel ...
Politics will matter greatly for the biotechnology and healthcare sectors. On Thursday, President-elect Trump said that ...
Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...
Why one trial participant's healthy birth after her CAR-T treatment for lupus is catching resesarchers' attention: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback